» Articles » PMID: 9560242

A Role for Pak Protein Kinases in Schwann Cell Transformation

Overview
Specialty Science
Date 1998 Jun 6
PMID 9560242
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Neurofibromatosis type 1 (NF1), a common autosomal dominant disorder caused by loss of the NF1 gene, is characterized clinically by neurofibromas and more rarely by neurofibrosarcomas. Neurofibromin, the protein encoded by NF1, possesses an intrinsic GTPase accelerating activity for the Ras proto-oncogene. Through this activity, it is a negative regulator of Ras. The Pak protein kinase is a candidate for a downstream signaling protein that may mediate Ras signals because it is activated by Rac and Cdc42, two small G proteins required for Ras signaling. Here, we use Pak mutants to explore the role of Pak in Ras signaling in Schwann cells, the cells affected in NF1. Whereas an activated Pak mutant does not transform cells, dominant negative Pak mutants are potent inhibitors of Ras transformation of rat Schwann cells and of a neurofibrosarcoma cell line from an NF1 patient. Although activated Pak stimulated jun-N-terminal kinase, inhibition of Ras transformation by dominant negative Pak did not require inhibition of jun-N-terminal kinase. Instead, the Pak mutants appeared to inhibit transformation by preventing Ras activation of the ERK/mitogen-activated protein kinase cascade. These results have implications for our understanding of NF1 because a neurofibrosarcoma cell line derived from a patient with NF1 was reverted by stable expression of the Pak dominant negative mutants.

Citing Articles

Systems Biology Approaches Reveal Potential Phenotype-Modifier Genes in Neurofibromatosis Type 1.

Kowalski T, Reis L, Andreis T, Ashton-Prolla P, Rosset C Cancers (Basel). 2020; 12(9).

PMID: 32858845 PMC: 7565824. DOI: 10.3390/cancers12092416.


Phosphorylation-dependent activity-based conformational changes in P21-activated kinase family members and screening of novel ATP competitive inhibitors.

Gul M, Fakhar M, Najumuddin , Rashid S PLoS One. 2019; 14(11):e0225132.

PMID: 31738805 PMC: 6860928. DOI: 10.1371/journal.pone.0225132.


Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis.

Semenova G, Stepanova D, Dubyk C, Handorf E, Deyev S, Lazar A Oncogene. 2017; 36(38):5421-5431.

PMID: 28534510 PMC: 5608634. DOI: 10.1038/onc.2017.143.


Comprehensive pharmacological profiling of neurofibromatosis cell lines.

Guo J, Grovola M, Xie H, Coggins G, Duggan P, Hasan R Am J Cancer Res. 2017; 7(4):923-934.

PMID: 28469964 PMC: 5411799.


Targeting PAK1.

Semenova G, Chernoff J Biochem Soc Trans. 2017; 45(1):79-88.

PMID: 28202661 PMC: 5973817. DOI: 10.1042/BST20160134.


References
1.
Phillips P, Levow C, CATTERALL M, COLVIN O, Pastan I, Brem H . Transforming growth factor-alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE38) treatment of subcutaneous and intracranial human glioma and medulloblastoma xenografts in athymic mice. Cancer Res. 1994; 54(4):1008-15. View

2.
Sheela S, Riccardi V, Ratner N . Angiogenic and invasive properties of neurofibroma Schwann cells. J Cell Biol. 1990; 111(2):645-53. PMC: 2116200. DOI: 10.1083/jcb.111.2.645. View

3.
Symons M . The Rac and Rho pathways as a source of drug targets for Ras-mediated malignancies. Curr Opin Biotechnol. 1995; 6(6):668-74. DOI: 10.1016/0958-1669(95)80110-3. View

4.
Marshall C . Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell. 1995; 80(2):179-85. DOI: 10.1016/0092-8674(95)90401-8. View

5.
Viskochil D, Buchberg A, Xu G, Cawthon R, Stevens J, Wolff R . Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell. 1990; 62(1):187-92. DOI: 10.1016/0092-8674(90)90252-a. View